NEW YORK, March 02, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of PixarBio Corporation securities (OTCQX:PXRB): (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017, both dates inclusive (the “Class Period”) of the March 27, 2016 lead plaintiff deadline in the first-filed class action filed by Rosen Law Firm. The lawsuit seeks to recover damages for PixarBio investors under the federal securities laws.
To join the PixarBio class action, go to http://www.rosenlegal.com/cases-1034.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) PixarBio’s assertions in press releases, third-party promotional materials, and PixarBio’s Form S-1 concerning, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees and PixarBio’s’ current and prospective development efforts lacked veracity; and; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 27, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1034.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 



